WHOOP’s $10B Valuation Signals Wearables Are No Longer Just Fitness Tools

WHOOP closed a $575 million Series G round on March 31, 2026. This lifted its valuation to $10.1 billion, nearly triple its previous $3.6 billion mark. The Boston-based wearable company is pushing further into personalized, preventive health. Furthermore, the raise brings together sovereign wealth funds, major health institutions, and high profile athletes. This signals broad confidence in the platform’s direction beyond fitness tracking.

A new chapter for WHOOP

Founded in 2012, WHOOP reported 103% year over year bookings growth in 2025 and reached a $1.1 billion bookings run rate. The company is now operating cash flow positive. The funding round was led by Collaborative Fund and included the Qatar Investment Authority, Mubadala Investment Company, Abbott, Mayo Clinic, and athletes LeBron James and Cristiano Ronaldo.

Platform, not just a band

WHOOP’s current health platform includes an FDA cleared ECG, Blood Pressure Insights, a Healthspan longevity feature, and Advanced Labs blood biomarker analysis. In March 2026, the company broadened its Advanced Labs offering with a Women’s Health Specialized Blood Biomarker Panel. This continues its push into clinical grade wearable health. WHOOP reports that members who wear the device daily increase weekly exercise by more than 90 minutes. Additionally, members gain over two additional hours of sleep per week.

Where the money goes

WHOOP plans to use the capital for international expansion, R&D, and scaling its platform globally. This includes its first overseas performance R&D facility, WHOOP Labs Doha in Qatar. The company currently has 2.5 million members worldwide. An IPO has been positioned as a longer term milestone.

The competitive context

The rise arrives as wearables increasingly converge around diagnostics and long-term health guidance, with Apple Watch, Oura Ring, and WHOOP all expanding into medical grade territory. WHOOP’s move to integrate ECG, blood pressure, and biomarker analysis positions it as a platform play rather than a hardware product, a distinction that may matter in a market where device commoditization is accelerating. For collectors, athletes, and everyday users, the bet is on daily data becoming clinical currency.